{"ticker": {"uuid": "f63e4963-e855-4c71-892d-92d02934b405", "symbol": "HURA", "name": "TuHURA Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form DEF 14A TuHURA Biosciences For: 9 July By Investing.com", "summary": "Investing.com reports that TuHURA Biosciences filed a Form DEF 14A on July 9. The article provides this concise financial news, attributing the information to Reuters. It does not elaborate on the contents or implications of the filing.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-tuhura-biosciences-for-9-july-93CH-2593813", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T22:11:26", "published_display": "09 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences (HURA) Stock Forum and Discussion", "summary": "This article provides a forum for discussion regarding TuHURA Biosciences (HURA) stock. Investors and interested parties can use this platform to share insights and opinions about the company's performance and future prospects.", "url": "https://www.moomoo.com/stock/HURA-US/community?chain_id=Name1K9-3FXPhg.1l11rg0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A64,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fprofile%2F%E5%8C%85%E5%B0%8F%E5%A7%90%E8%80%81%E5%85%AC%E7%9A%84%E5%85%BB%E8%80%81%E9%87%91-104453163%2Fpost%2Foriginal%22%7D", "source_name": "Moomoo", "published_at": "2026-07-09T04:40:50", "published_display": "09 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. (NASDAQ: HURA) Files 8-K Report Detailing Company Information and Compliance Updates \u2013 Minichart", "summary": "TuHURA Biosciences, Inc. (NASDAQ: HURA) has filed an 8-K report detailing a new direct financial obligation and referencing a prior loan agreement from April 22, 2026. The report emphasizes the company's dependency on this loan for capital, noting potential risks due to the lende", "url": "https://www.minichart.com.sg/2026/07/07/tuhura-biosciences-inc-nasdaq-hura-files-8-k-report-detailing-company-information-and-compliance-updates/", "source_name": "Minichart", "published_at": "2026-07-08T03:40:43", "published_display": "08 Jul 2026 03:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell 3000E Growth Benchmark", "summary": "TuHURA Biosciences, Inc. (NasdaqCM:HURA) has been removed from the Russell 3000E Growth Benchmark, as announced on June 28, 2026. This follows several other removals from various Russell indices around the same date, including the Russell 2000, Russell 3000, and Russell 2500 indi", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-3000e-growth-benchmark-ce7f5fddd980f627", "source_name": "www.marketscreener.com", "published_at": "2026-07-02T18:12:10", "published_display": "02 Jul 2026 18:12", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2000 Dynamic Index", "summary": "TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 2000 Dynamic Index, as well as several other Russell indices, including the Russell 3000E, Russell Small Cap Completeness, Russell 2500, Russell 3000, Russell 2000, and Russell Small Cap Comp Growth Bench", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-2000-dynamic-index-ce7f5fdfdc8dff26", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:39:11", "published_display": "29 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of TuHURA Biosciences, Inc. \u2013 FWB:PL3", "summary": "This article displays financial information for TuHURA Biosciences, Inc. under its Frankfurt Stock Exchange ticker FWB:PL3. Specifically, it presents the company's enterprise value to EBIT forward, noting that the market is currently closed with no trades. The content primarily s", "url": "https://www.tradingview.com/symbols/FWB-PL3/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:39:11", "published_display": "29 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2500 Index", "summary": "TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 2500 Index as of June 29, 2026. This exclusion is one of several recent removals from various Russell indices, including the Russell 2000 Dynamic, 3000E, Small Cap Completeness, 3000, 2000, and Small Cap ", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-2500-index-ce7f5fdfda89f722", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:46:00", "published_display": "29 Jun 2026 13:46", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell Small Cap Comp Growth Benchmark", "summary": "TuHURA Biosciences, Inc. (NasdaqCM:HURA) has been removed from the Russell Small Cap Comp Growth Benchmark. This news follows several recent developments for the company, including filing a New Drug Application for an antibody to treat AML and reporting Q1 2026 earnings results.", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-small-cap-comp-growth-benchmark-ce7f5fdede88f32d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:11:14", "published_display": "29 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 3000 Index", "summary": "TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 3000 Index, according to an announcement published on June 29, 2026, at 10:11 am EDT, based on S&P Capital IQ data. This change is part of broader index adjustments, as the company was also dropped from s", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-3000-index-ce7f5fdfd98cf621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:11:00", "published_display": "29 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of TuHURA Biosciences, Inc. \u2013 DUS:PL3", "summary": "This article provides the \"Price to earnings forward\" value for TuHURA Biosciences, Inc., identified by its Dusseldorf Stock Exchange symbol DUS:PL3. The content indicates that the market is closed, and no trades have occurred for this specific financial metric. The information i", "url": "https://www.tradingview.com/symbols/DUS-PL3/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:41:10", "published_display": "28 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Return on equity % of TuHURA Biosciences, Inc. \u2013 DUS:PL3", "summary": "This article provides financial information for TuHURA Biosciences, Inc. (DUS:PL3) on the TradingView platform. It specifically focuses on the company's Return on Equity (%) metric. The content highlights that market is currently closed with no trades and lists various sections a", "url": "https://www.tradingview.com/symbols/DUS-PL3/financials-statistics-and-ratios/return-on-equity/", "source_name": "TradingView", "published_at": "2026-06-28T01:09:54", "published_display": "28 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of TuHURA Biosciences, Inc. \u2013 NASDAQ:HURA", "summary": "This article provides financial information for TuHURA Biosciences, Inc. (NASDAQ:HURA), specifically focusing on its enterprise value to EBITDA forward. While the article text itself is minimal, it highlights access to detailed financial data and other market information for the ", "url": "https://www.tradingview.com/symbols/NASDAQ-HURA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:40:47", "published_display": "27 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of TuHURA Biosciences, Inc. \u2013 NASDAQ:HURA", "summary": "This article provides the enterprise value to revenue forward for TuHURA Biosciences, Inc. (NASDAQ: HURA). It presents financial data within a TradingView context, displaying the stock's performance and related information like historical financials, news, and community insights.", "url": "https://www.tradingview.com/symbols/NASDAQ-HURA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:40:16", "published_display": "27 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Balance Sheet \u2013 DUS:PL3", "summary": "TuHURA Biosciences, Inc.'s balance sheet for Q1 2026 shows total assets of 25.71 million EUR, a 10.40% increase from Q4 2025. Total liabilities also increased by 3.15% to 5.64 million EUR in the same quarter. The report provides a snapshot of the company's financial position and ", "url": "https://www.tradingview.com/symbols/DUS-PL3/financials-balance-sheet/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:16", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences (HURA) virtual annual meeting Aug 18; shareholders to vote on 1.88M-share issuance", "summary": "TuHURA Biosciences will hold its virtual annual meeting on August 18, 2026, where shareholders will vote on several proposals, including the election of six directors and the approval of issuing 1.88 million shares to Parkview Holdings One LLC. This share issuance is in connectio", "url": "https://www.stocktitan.net/sec-filings/HURA/pre-14a-tu-hura-biosciences-inc-nv-preliminary-proxy-statement-9ec5091c588b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:40:12", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Actuals & Estimates (NASDAQ:HURA)", "summary": "This article provides an overview of TuHURA Biosciences, Inc. (NASDAQ: HURA) stock performance, financial estimates, and analyst forecasts. It details the company's current stock price, market capitalization, historical highs and lows, and upcoming earnings report dates, while al", "url": "https://www.tradingview.com/symbols/NASDAQ-HURA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:12", "published_display": "26 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Actuals & Estimates (MUN:PL3)", "summary": "This article provides an overview of TuHURA Biosciences, Inc. (MUN:PL3) financials, including actual reported data and analyst estimates. It covers historical stock performance like all-time high and low prices, upcoming earnings dates, and past earnings and revenue figures. Addi", "url": "https://www.tradingview.com/symbols/MUN-PL3/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:07", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PL3 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for TuHURA Biosciences, Inc. (PL3) stock, including price targets and analyst ratings. It highlights the stock's highest and lowest prices, upcoming earnings reports, and financial performance such as EPS, revenue, and net income. The article also", "url": "https://www.tradingview.com/symbols/FWB-PL3/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:12:11", "published_display": "25 Jun 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Files Form 8-K with Nasdaq: Corporate Information, Address, and Key Details", "summary": "TuHURA Biosciences, Inc. (NASDAQ: HURA) announced significant updates regarding its 2026 Annual Meeting of Stockholders, which will be held virtually on August 18, 2026. Due to this change, the deadline for shareholder proposals and director nominations for proxy materials has be", "url": "https://www.minichart.com.sg/2026/06/18/tuhura-biosciences-inc-files-form-8-k-with-nasdaq-corporate-information-address-and-key-details/", "source_name": "Minichart", "published_at": "2026-06-18T03:10:45", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc (HURA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for TuHURA Biosciences Inc (HURA). It notes that no dividends have been distributed in the past five years. The stock split section details several merger-related stock splits with a ratio of 35\u21921 in October 20", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hura/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:45", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc (HURA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a brief valuation analysis for TuHURA Biosciences Inc (HURA), noting that key financial data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. It presents the stock's current price, market capitalization, and a general overvi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hura/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T08:10:45", "published_display": "17 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc (HURA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of TuHURA Biosciences Inc (HURA), primarily noting the lack of essential disclosed data for profitability, operational efficiency, growth potential, and shareholder returns. It highlights the company's current market cap, stock pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hura/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T08:09:46", "published_display": "17 Jun 2026 08:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc (HURA) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" overview for TuHURA Biosciences Inc (HURA), detailing institutional shareholdings and recent changes in those holdings. Key shareholders like Vijay Patel, Matthew Nachtrab, and Samir Rashmikant Patel are listed, along with Black", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hura/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T07:09:46", "published_display": "17 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates TuHURA Biosciences stock rating on AML progress By Investing.com", "summary": "Citizens has reaffirmed its \"Market Outperform\" rating and $9.00 price target for TuHURA Biosciences (NASDAQ:HURA) after the company filed an Investigational New Drug (IND) application for its anti-VISTA monoclonal antibody, TBS-2025. This move follows FDA guidance for developing", "url": "https://ca.investing.com/news/stock-market-news/citizens-reiterates-tuhura-biosciences-stock-rating-on-aml-progress-93CH-4692714", "source_name": "Investing.com Canada", "published_at": "2026-06-16T10:39:57", "published_display": "16 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates TuHURA Biosciences stock rating on AML progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOaDFtOWJFU3c0NVRNQzJMeVdOT205ODAtSnlLWThXcE9HcXB0S2NmTXBlWkU1b085RkdRcFlTUGl4X1h0ZVM1eGFrZzFVTW5icG9nUkdjclNsX0J1X0ZLTmZETVpJUmZCX2JGX3ZSMmd4T1N3RjY4bnZ5bFNqdEgzOFlnekRaX2ZFeE5jSnR4SWs0QUF1R0hCaWIxRGwxNTNzaml0NnNIa2gta3d2NW9kTWt5djhZVTdzLWhLeGZodmNoUFF1U2c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences (NASDAQ:HURA) files IND for TBS-2025", "summary": "TuHURA Biosciences (NASDAQ:HURA) has filed an Investigational New Drug (IND) application with the FDA for its VISTA-inhibiting antibody, TBS-2025, aimed at treating specific subsets of acute myeloid leukemia (AML) and other blood-related cancers. The company plans to initiate a P", "url": "https://grafa.com/en/news/united-states/tuhura-biosciences-files-ind-tbs-2025", "source_name": "grafa.com", "published_at": "2026-06-15T14:14:04", "published_display": "15 Jun 2026 14:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Files New Drug Application for Evaluation of Antibody to Treat Subsets of AML", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tuhura-biosciences-files-drug-application-123348324.html", "source_name": "MT Newswires", "published_at": "2026-06-15T12:33:48+00:00", "published_display": "15 Jun 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA files IND for TBS-2025 in blood cancer study", "summary": "TuHURA Biosciences, a clinical-stage biotech company, has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA inhibiting antibody, to treat acute myeloid leukemia and other blood cancers. The company plans to initiate a Phase 1b/2 study in the s", "url": "https://www.investing.com/news/company-news/tuhura-files-ind-for-tbs2025-in-blood-cancer-study-93CH-4741906", "source_name": "Investing.com", "published_at": "2026-06-15T12:14:04", "published_display": "15 Jun 2026 12:14", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers", "summary": "TuHURA Biosciences announced it has filed an Investigational New Drug (IND) application with the FDA for its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of AML and other blood cancers. The company targets initiating a Phase 1b/2 study in the second hal", "url": "https://www.prnewswire.com/news-releases/tuhura-biosciences-files-investigational-new-drug-application-for-evaluation-of-the-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers-302799770.html", "source_name": "PR Newswire", "published_at": "2026-06-15T12:14:03", "published_display": "15 Jun 2026 12:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New antibody to test in specific leukemia mutations as TuHURA files with FDA", "summary": "TuHURA Biosciences has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA inhibiting antibody, to treat molecularly defined subsets of AML and other blood cancers. The company plans a combined Phase 1b/2 study, targeting initiation in the secon", "url": "https://www.stocktitan.net/news/HURA/tu-hura-biosciences-files-investigational-new-drug-application-for-ravvez6f01qz.html", "source_name": "Stock Titan", "published_at": "2026-06-15T05:46:40", "published_display": "15 Jun 2026 05:46", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Misses Estimates, Stock Slides on Higher Cash Burn and Pre-Revenue Status - Earnings Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxPa2pDSF9PSjRyNXV0c2M2NF9Nd2ZkNzdEcDFHZk85TTFrQ1JLTGpYcFRJcVlYZUd6bEZjdlNCZUQ4LVRXOFZObll5MHByd2p4a21xREViTURDOHlpZHF1UkluS1FCYXN4ekl0eGRwb3BZVTZpV1gzcTJ6enBOYmpZNXVxNkphTHVSNGhkcEJudnFtS016cmZQR0ZjYUwzT3pjT1ZUeUxZQUVOMTYwcl9WdmsxdVNvejliSU9DekdNNFZzZUpfY0s1S0NJaXRDYTlqTVZvR3JYb3RkMGM3bkV5cGlWbDF3QzI0ZFhGNWN2WlNfdmVwTEE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA (NASDAQ: HURA) taps $1.7M from $50M revolving loan facility", "summary": "TuHURA Biosciences (NASDAQ: HURA) has drawn $1.7 million from its $50 million revolving credit facility with Parkview Holdings One LLC. This initial draw, made on May 26, 2026, will be used for general corporate purposes, providing additional liquidity for operations and developm", "url": "https://www.stocktitan.net/sec-filings/HURA/8-k-tu-hura-biosciences-inc-nv-reports-material-event-f630f5a81a52.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:39:52", "published_display": "29 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tuhura-biosciences-reports-first-quarter-210000025.html", "source_name": "PR Newswire", "published_at": "2026-05-15T21:00:00+00:00", "published_display": "15 May 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tuhura-biosciences-present-4th-annual-113000838.html", "source_name": "PR Newswire", "published_at": "2026-05-12T11:30:00+00:00", "published_display": "12 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tuhura-biosciences-announces-50-million-113000809.html", "source_name": "PR Newswire", "published_at": "2026-04-22T11:30:00+00:00", "published_display": "22 Apr 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQWU1oWHBDYWFmOXZJZ1FLc2hEblJJRnlfUkZZZ1BEN1l2Z1VEVzNDaTNIWnJFdWlyQnV3V1kxOG16RXY5elN0VmNkeDJJQndQeWV6QTFkSmptaXJsUVVubjRjSlBpdlRFMFZNT3NHRXRyRjNyM19IMTR4djJ0WUM3eUtpRWJvcThVczJ5WlhmR0VaV0p0bUlpS1dtTERiTEJyUkZrVzZPcw?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. (NASDAQ:HURA): Is Breakeven Near?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNMEk2MUVJcFJpNDU3cmpNNjlvaVNxd0JlMFZLUHpjcnc2QXlxNlZOYVU4UkZYVUpjX0FZTmVHVkQxc044UE9DRGRRWkQyVzNCck1pbzFEbXZYZHAxVXNuVkl4UnJrTWdEY1lQZTJSWjdHdF9aUVFlUldHcGJtd0dpMXJGOTlxV1J3Qi1IU0Q2VExGT0NNMGdpN3hDVFI4NGswcjZvZE5n?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Doctor behind 30 cancer approvals now steers TuHURA's AML effort", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQVDNGQ2lVejRBRFpDS0luX3NNNHM3M1A0ZmtMaDJuU25tVXY0RGR5b1Bnb24xSndqM3AwRm4yUTVvN1AxaFBTNUZRcVZPNXU4QWRqdC1zdjFxS0R0WEhMdGVMenVLNGh5eGVtalV1cl9Fc1hhNC1aUFR1cW90Zk10cDF4Q2hWYzFkMkRVaFcwc3lFTjNJVjFub0JBMUdnQVpIZTdYaWlmLXhVOHdCd2tpb1hWYUdZbjBVN1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Common Stock (HURA) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1ZTUg4bklEalFpQXpCalMzTGhEeXREcTdHbkpwX2RyaV9Tc0U1ellLdjE1MEJYMHdfM1puRjhjTWRqcXdnX2ZEMEstX2JNUVg2VXhjckY4dw?oc=5", "source_name": "Gotrade", "published_at": "2026-03-18T20:03:30+00:00", "published_display": "18 Mar 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNeWlQVUUtZm5xNHg3UWVRcHlMa2VJTFR3ekw2ZExnNElEQWlDRTBxbjJ5bnVXNGR2NjRHaEVST3lYU0MwRURwWlJsNTdmd0F0cXJRRUMxQVYwQUdoekYxN1pOT3NveXJVWG11eTZpNmcwcmdvZXlSM3dwRk1ERFJRb0xpdWtSU1JWSHJiSjB4SzlVc28xV21sQjJ1ZVlmZFhCdy0wd3BJd2ZaVEZkWmVyQjNQeXIwZ3BINmZzNnpuN20zVy13RURTQ1lpT2FtQ2pZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgJBVV95cUxOUmtEVURrVktoSjFuanlqYl9JR1VRRzRKRm9qOERWRHNzM0lxQ3R1SzhCNjJFNnp6TnVYWmRZc0NEMm1Gc0NFMjVVZVIzNzNZR3h5N1ZRbnpCakpMTVg0N0lONEl0NnJEUEpuXzhlRnJMekl5WGNmM0ZwVTJqMkJia25RQllvNzBpcFR5YjlIN2ZleGh3Z3Jwd24xQWIwZUR6NWl3b05zZnRhRFp4QmR6WEc2TmFobHl5SkN5MlZJWEVaNTl5TlNGVG1nMVdFbVJkLWVBLVdHcUlpSXFGVnJVSFdIbDdiZEVCRm1aTlV2VjJ5MUgwV0pqQ1FhaGlZV0JYbnc4Tmk5dGZXNFh4ZUhXSnpFQmFEQjlIcjgyc3JvbWRZaVZGcFpQQXU1bmlPam9qS1NzU1JNYVBHVWhpZ0E?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxONThocXpBVUgxczRTZnBKRUo4RWkxS0dJdl9tN0lad1V4VkVRNDNqYmRLdzZXU01hd3JSNl9iUWpDWmNRdV9yQkJ1R05PT0hXZnRFVEhzSnVwREF3NUV3eHU4TVYwRlpxbTlWVG1IZUg3aHlrVXpGbUw0Tk9hdklrTVhQSGxCYzFranFOVnYyMmlqWE45MUstcEE1SjFRUnlOUTl2aXdBcE1nQ0VjRi1qcmRWb0tOTTdDaHdLaWttUUl0T0s2SVJB?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences announces $15.6 million registered direct offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQR3VIUklONE5LNEpOZVR0SEJpWjBtWTVRclpfMlc2MXE4b2JpNzMyNS1hSVRuMXJOVlpzTnZBQTg5S0M4SVhURnA0LUdUOUNoenVIMFpYbFlpT293X1U2VTROUEtpbzN4Mjl3bzJMdTh0MkNKNzRjcHlHb1hwbjN1TVN5QjItUUVHSTFaZ2Vfc2JmMU50cGRpa0h3Mi1tNHRHME5tN0Q5Q0h3NTgwMEdOVU90VzdFZWxTNWtJM05rLWV1Zw?oc=5", "source_name": "Investing.com", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The recent pullback must have dismayed TuHURA Biosciences, Inc. (NASDAQ:HURA) insiders who own 43% of the company", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HURA Stock Price and Chart \u2014 NASDAQ:HURA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1sYTNGVE1naVdiNmdYOFNkcnVzOVdVc2NhLXpTczBhLXdEN3pkWDJHM0l0UHMxWGJDMnFMblVKU1BUb0NvaS1OTEp5aXhfNW5ieWg3QlI5QWVJNTFS?oc=5", "source_name": "TradingView", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-03T07:00:00+00:00", "published_display": "03 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOcUJaeWlLNHVmaGlNN2VRYmpZZlRuc3BFekNPYWUxcFFEd1lwd1BJekJkSXg0TkloaEZOR1o2ZjVmUEFETEp4WEtXazhnYThpV0gzOUdoUFI5clhkYU1kV2d5LXNWZDdTNEtKTzFlSDRMTC1LLWM2TTUta2lpZUpuT1NPTF8?oc=5", "source_name": "Market source", "published_at": "2025-04-18T07:00:00+00:00", "published_display": "18 Apr 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences (HURA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9zVkFNbDIwam1oOTVzVHMwdURvc0dxZk0wbUZKMXIxNWdrLTNmN281aHc5a3RJbUlHZXB4Y1Brd25zNnNvZ2tpS1hUcEw5WENWX2tEZThSa2lNZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-11-05T15:13:54+00:00", "published_display": "05 Nov 2024 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxPMkNFOVFBSlNXVmFQRlFCeEhCQnFDSDZBQWI4UHVhTWp4bXJEWXNVcVVDYUtVaDFRd0QyVXpvZTVueF9OQWNsYUYzTGxwVzk4N19FZUtJWTdjZ1AtQ3pHcWJMX1prdmJpTGxnU3I3Z3RNV05VMjRnSnhncDUxc19KS2FKaW9WZUJQZFQ3R3c0NzhRdGRJdGRIaFBneC0wTVZaVkhHRGo0LXhTdlkzMGVJbkRrSW5aQjZGRHlYbVhoQldFVWlrNGo5d3hid2RtTjFGM0hfMDRkZGxCeEJRZ3gxVFNnRGJXdzNjenRhUkNqeDJ2UzQ3N0NTNmFoUjRqbzE4ZmJackpHZXNwZw?oc=5", "source_name": "PR Newswire", "published_at": "2024-10-16T07:00:00+00:00", "published_display": "16 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form DEF 14A TuHURA Biosciences For: 9 July By Investing.com", "summary": "Investing.com reports that TuHURA Biosciences filed a Form DEF 14A on July 9. The article provides this concise financial news, attributing the information to Reuters. It does not elaborate on the contents or implications of the filing.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-tuhura-biosciences-for-9-july-93CH-2593813", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T22:11:26", "published_display": "09 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences (HURA) Stock Forum and Discussion", "summary": "This article provides a forum for discussion regarding TuHURA Biosciences (HURA) stock. Investors and interested parties can use this platform to share insights and opinions about the company's performance and future prospects.", "url": "https://www.moomoo.com/stock/HURA-US/community?chain_id=Name1K9-3FXPhg.1l11rg0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A64,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fprofile%2F%E5%8C%85%E5%B0%8F%E5%A7%90%E8%80%81%E5%85%AC%E7%9A%84%E5%85%BB%E8%80%81%E9%87%91-104453163%2Fpost%2Foriginal%22%7D", "source_name": "Moomoo", "published_at": "2026-07-09T04:40:50", "published_display": "09 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. (NASDAQ: HURA) Files 8-K Report Detailing Company Information and Compliance Updates \u2013 Minichart", "summary": "TuHURA Biosciences, Inc. (NASDAQ: HURA) has filed an 8-K report detailing a new direct financial obligation and referencing a prior loan agreement from April 22, 2026. The report emphasizes the company's dependency on this loan for capital, noting potential risks due to the lende", "url": "https://www.minichart.com.sg/2026/07/07/tuhura-biosciences-inc-nasdaq-hura-files-8-k-report-detailing-company-information-and-compliance-updates/", "source_name": "Minichart", "published_at": "2026-07-08T03:40:43", "published_display": "08 Jul 2026 03:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell 3000E Growth Benchmark", "summary": "TuHURA Biosciences, Inc. (NasdaqCM:HURA) has been removed from the Russell 3000E Growth Benchmark, as announced on June 28, 2026. This follows several other removals from various Russell indices around the same date, including the Russell 2000, Russell 3000, and Russell 2500 indi", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-3000e-growth-benchmark-ce7f5fddd980f627", "source_name": "www.marketscreener.com", "published_at": "2026-07-02T18:12:10", "published_display": "02 Jul 2026 18:12", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2000 Dynamic Index", "summary": "TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 2000 Dynamic Index, as well as several other Russell indices, including the Russell 3000E, Russell Small Cap Completeness, Russell 2500, Russell 3000, Russell 2000, and Russell Small Cap Comp Growth Bench", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-2000-dynamic-index-ce7f5fdfdc8dff26", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:39:11", "published_display": "29 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of TuHURA Biosciences, Inc. \u2013 FWB:PL3", "summary": "This article displays financial information for TuHURA Biosciences, Inc. under its Frankfurt Stock Exchange ticker FWB:PL3. Specifically, it presents the company's enterprise value to EBIT forward, noting that the market is currently closed with no trades. The content primarily s", "url": "https://www.tradingview.com/symbols/FWB-PL3/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:39:11", "published_display": "29 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2500 Index", "summary": "TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 2500 Index as of June 29, 2026. This exclusion is one of several recent removals from various Russell indices, including the Russell 2000 Dynamic, 3000E, Small Cap Completeness, 3000, 2000, and Small Cap ", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-2500-index-ce7f5fdfda89f722", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:46:00", "published_display": "29 Jun 2026 13:46", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell Small Cap Comp Growth Benchmark", "summary": "TuHURA Biosciences, Inc. (NasdaqCM:HURA) has been removed from the Russell Small Cap Comp Growth Benchmark. This news follows several recent developments for the company, including filing a New Drug Application for an antibody to treat AML and reporting Q1 2026 earnings results.", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-small-cap-comp-growth-benchmark-ce7f5fdede88f32d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:11:14", "published_display": "29 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 3000 Index", "summary": "TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 3000 Index, according to an announcement published on June 29, 2026, at 10:11 am EDT, based on S&P Capital IQ data. This change is part of broader index adjustments, as the company was also dropped from s", "url": "https://www.marketscreener.com/news/tuhura-biosciences-inc-nasdaqcm-hura-dropped-from-russell-3000-index-ce7f5fdfd98cf621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:11:00", "published_display": "29 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of TuHURA Biosciences, Inc. \u2013 DUS:PL3", "summary": "This article provides the \"Price to earnings forward\" value for TuHURA Biosciences, Inc., identified by its Dusseldorf Stock Exchange symbol DUS:PL3. The content indicates that the market is closed, and no trades have occurred for this specific financial metric. The information i", "url": "https://www.tradingview.com/symbols/DUS-PL3/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:41:10", "published_display": "28 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Return on equity % of TuHURA Biosciences, Inc. \u2013 DUS:PL3", "summary": "This article provides financial information for TuHURA Biosciences, Inc. (DUS:PL3) on the TradingView platform. It specifically focuses on the company's Return on Equity (%) metric. The content highlights that market is currently closed with no trades and lists various sections a", "url": "https://www.tradingview.com/symbols/DUS-PL3/financials-statistics-and-ratios/return-on-equity/", "source_name": "TradingView", "published_at": "2026-06-28T01:09:54", "published_display": "28 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of TuHURA Biosciences, Inc. \u2013 NASDAQ:HURA", "summary": "This article provides financial information for TuHURA Biosciences, Inc. (NASDAQ:HURA), specifically focusing on its enterprise value to EBITDA forward. While the article text itself is minimal, it highlights access to detailed financial data and other market information for the ", "url": "https://www.tradingview.com/symbols/NASDAQ-HURA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:40:47", "published_display": "27 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of TuHURA Biosciences, Inc. \u2013 NASDAQ:HURA", "summary": "This article provides the enterprise value to revenue forward for TuHURA Biosciences, Inc. (NASDAQ: HURA). It presents financial data within a TradingView context, displaying the stock's performance and related information like historical financials, news, and community insights.", "url": "https://www.tradingview.com/symbols/NASDAQ-HURA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:40:16", "published_display": "27 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Balance Sheet \u2013 DUS:PL3", "summary": "TuHURA Biosciences, Inc.'s balance sheet for Q1 2026 shows total assets of 25.71 million EUR, a 10.40% increase from Q4 2025. Total liabilities also increased by 3.15% to 5.64 million EUR in the same quarter. The report provides a snapshot of the company's financial position and ", "url": "https://www.tradingview.com/symbols/DUS-PL3/financials-balance-sheet/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:16", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences (HURA) virtual annual meeting Aug 18; shareholders to vote on 1.88M-share issuance", "summary": "TuHURA Biosciences will hold its virtual annual meeting on August 18, 2026, where shareholders will vote on several proposals, including the election of six directors and the approval of issuing 1.88 million shares to Parkview Holdings One LLC. This share issuance is in connectio", "url": "https://www.stocktitan.net/sec-filings/HURA/pre-14a-tu-hura-biosciences-inc-nv-preliminary-proxy-statement-9ec5091c588b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:40:12", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Actuals & Estimates (NASDAQ:HURA)", "summary": "This article provides an overview of TuHURA Biosciences, Inc. (NASDAQ: HURA) stock performance, financial estimates, and analyst forecasts. It details the company's current stock price, market capitalization, historical highs and lows, and upcoming earnings report dates, while al", "url": "https://www.tradingview.com/symbols/NASDAQ-HURA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:12", "published_display": "26 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Actuals & Estimates (MUN:PL3)", "summary": "This article provides an overview of TuHURA Biosciences, Inc. (MUN:PL3) financials, including actual reported data and analyst estimates. It covers historical stock performance like all-time high and low prices, upcoming earnings dates, and past earnings and revenue figures. Addi", "url": "https://www.tradingview.com/symbols/MUN-PL3/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:07", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PL3 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for TuHURA Biosciences, Inc. (PL3) stock, including price targets and analyst ratings. It highlights the stock's highest and lowest prices, upcoming earnings reports, and financial performance such as EPS, revenue, and net income. The article also", "url": "https://www.tradingview.com/symbols/FWB-PL3/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:12:11", "published_display": "25 Jun 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Files Form 8-K with Nasdaq: Corporate Information, Address, and Key Details", "summary": "TuHURA Biosciences, Inc. (NASDAQ: HURA) announced significant updates regarding its 2026 Annual Meeting of Stockholders, which will be held virtually on August 18, 2026. Due to this change, the deadline for shareholder proposals and director nominations for proxy materials has be", "url": "https://www.minichart.com.sg/2026/06/18/tuhura-biosciences-inc-files-form-8-k-with-nasdaq-corporate-information-address-and-key-details/", "source_name": "Minichart", "published_at": "2026-06-18T03:10:45", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc (HURA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for TuHURA Biosciences Inc (HURA). It notes that no dividends have been distributed in the past five years. The stock split section details several merger-related stock splits with a ratio of 35\u21921 in October 20", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hura/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:45", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc (HURA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a brief valuation analysis for TuHURA Biosciences Inc (HURA), noting that key financial data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. It presents the stock's current price, market capitalization, and a general overvi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hura/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T08:10:45", "published_display": "17 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc (HURA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of TuHURA Biosciences Inc (HURA), primarily noting the lack of essential disclosed data for profitability, operational efficiency, growth potential, and shareholder returns. It highlights the company's current market cap, stock pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hura/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T08:09:46", "published_display": "17 Jun 2026 08:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc (HURA) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" overview for TuHURA Biosciences Inc (HURA), detailing institutional shareholdings and recent changes in those holdings. Key shareholders like Vijay Patel, Matthew Nachtrab, and Samir Rashmikant Patel are listed, along with Black", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hura/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T07:09:46", "published_display": "17 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates TuHURA Biosciences stock rating on AML progress By Investing.com", "summary": "Citizens has reaffirmed its \"Market Outperform\" rating and $9.00 price target for TuHURA Biosciences (NASDAQ:HURA) after the company filed an Investigational New Drug (IND) application for its anti-VISTA monoclonal antibody, TBS-2025. This move follows FDA guidance for developing", "url": "https://ca.investing.com/news/stock-market-news/citizens-reiterates-tuhura-biosciences-stock-rating-on-aml-progress-93CH-4692714", "source_name": "Investing.com Canada", "published_at": "2026-06-16T10:39:57", "published_display": "16 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates TuHURA Biosciences stock rating on AML progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOaDFtOWJFU3c0NVRNQzJMeVdOT205ODAtSnlLWThXcE9HcXB0S2NmTXBlWkU1b085RkdRcFlTUGl4X1h0ZVM1eGFrZzFVTW5icG9nUkdjclNsX0J1X0ZLTmZETVpJUmZCX2JGX3ZSMmd4T1N3RjY4bnZ5bFNqdEgzOFlnekRaX2ZFeE5jSnR4SWs0QUF1R0hCaWIxRGwxNTNzaml0NnNIa2gta3d2NW9kTWt5djhZVTdzLWhLeGZodmNoUFF1U2c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences (NASDAQ:HURA) files IND for TBS-2025", "summary": "TuHURA Biosciences (NASDAQ:HURA) has filed an Investigational New Drug (IND) application with the FDA for its VISTA-inhibiting antibody, TBS-2025, aimed at treating specific subsets of acute myeloid leukemia (AML) and other blood-related cancers. The company plans to initiate a P", "url": "https://grafa.com/en/news/united-states/tuhura-biosciences-files-ind-tbs-2025", "source_name": "grafa.com", "published_at": "2026-06-15T14:14:04", "published_display": "15 Jun 2026 14:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Files New Drug Application for Evaluation of Antibody to Treat Subsets of AML", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tuhura-biosciences-files-drug-application-123348324.html", "source_name": "MT Newswires", "published_at": "2026-06-15T12:33:48+00:00", "published_display": "15 Jun 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA files IND for TBS-2025 in blood cancer study", "summary": "TuHURA Biosciences, a clinical-stage biotech company, has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA inhibiting antibody, to treat acute myeloid leukemia and other blood cancers. The company plans to initiate a Phase 1b/2 study in the s", "url": "https://www.investing.com/news/company-news/tuhura-files-ind-for-tbs2025-in-blood-cancer-study-93CH-4741906", "source_name": "Investing.com", "published_at": "2026-06-15T12:14:04", "published_display": "15 Jun 2026 12:14", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers", "summary": "TuHURA Biosciences announced it has filed an Investigational New Drug (IND) application with the FDA for its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of AML and other blood cancers. The company targets initiating a Phase 1b/2 study in the second hal", "url": "https://www.prnewswire.com/news-releases/tuhura-biosciences-files-investigational-new-drug-application-for-evaluation-of-the-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers-302799770.html", "source_name": "PR Newswire", "published_at": "2026-06-15T12:14:03", "published_display": "15 Jun 2026 12:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New antibody to test in specific leukemia mutations as TuHURA files with FDA", "summary": "TuHURA Biosciences has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA inhibiting antibody, to treat molecularly defined subsets of AML and other blood cancers. The company plans a combined Phase 1b/2 study, targeting initiation in the secon", "url": "https://www.stocktitan.net/news/HURA/tu-hura-biosciences-files-investigational-new-drug-application-for-ravvez6f01qz.html", "source_name": "Stock Titan", "published_at": "2026-06-15T05:46:40", "published_display": "15 Jun 2026 05:46", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Misses Estimates, Stock Slides on Higher Cash Burn and Pre-Revenue Status - Earnings Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxPa2pDSF9PSjRyNXV0c2M2NF9Nd2ZkNzdEcDFHZk85TTFrQ1JLTGpYcFRJcVlYZUd6bEZjdlNCZUQ4LVRXOFZObll5MHByd2p4a21xREViTURDOHlpZHF1UkluS1FCYXN4ekl0eGRwb3BZVTZpV1gzcTJ6enBOYmpZNXVxNkphTHVSNGhkcEJudnFtS016cmZQR0ZjYUwzT3pjT1ZUeUxZQUVOMTYwcl9WdmsxdVNvejliSU9DekdNNFZzZUpfY0s1S0NJaXRDYTlqTVZvR3JYb3RkMGM3bkV5cGlWbDF3QzI0ZFhGNWN2WlNfdmVwTEE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA (NASDAQ: HURA) taps $1.7M from $50M revolving loan facility", "summary": "TuHURA Biosciences (NASDAQ: HURA) has drawn $1.7 million from its $50 million revolving credit facility with Parkview Holdings One LLC. This initial draw, made on May 26, 2026, will be used for general corporate purposes, providing additional liquidity for operations and developm", "url": "https://www.stocktitan.net/sec-filings/HURA/8-k-tu-hura-biosciences-inc-nv-reports-material-event-f630f5a81a52.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:39:52", "published_display": "29 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tuhura-biosciences-reports-first-quarter-210000025.html", "source_name": "PR Newswire", "published_at": "2026-05-15T21:00:00+00:00", "published_display": "15 May 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tuhura-biosciences-present-4th-annual-113000838.html", "source_name": "PR Newswire", "published_at": "2026-05-12T11:30:00+00:00", "published_display": "12 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tuhura-biosciences-announces-50-million-113000809.html", "source_name": "PR Newswire", "published_at": "2026-04-22T11:30:00+00:00", "published_display": "22 Apr 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQWU1oWHBDYWFmOXZJZ1FLc2hEblJJRnlfUkZZZ1BEN1l2Z1VEVzNDaTNIWnJFdWlyQnV3V1kxOG16RXY5elN0VmNkeDJJQndQeWV6QTFkSmptaXJsUVVubjRjSlBpdlRFMFZNT3NHRXRyRjNyM19IMTR4djJ0WUM3eUtpRWJvcThVczJ5WlhmR0VaV0p0bUlpS1dtTERiTEJyUkZrVzZPcw?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. (NASDAQ:HURA): Is Breakeven Near?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQdUtzaGg5N0NuMmRST0JDTzZPTlFhRU0tejd4SFFOdVNHRm53TzFlRGZtYmtGZjVDMEl5c1ZBaWc1WF94WmdwNkpZQ19WQWJOb1pTdUg3cC1KeEowZ2pUNmxTTFhxcEdZLWJRUkFfcC12WDhObDQ5MkNrb0FkazdkTHQwOHpiX25WLW1fU2tBeXk5NUNMOW40ZEdBSXROU1hGWkYxMHBvTkxRZGxvalNqcTVYRnA5Q0tqcGh0OHRZRkN3NXV6dXB5MXhDbEVpeV9oM1J3N1V4YWxrSVHSAeABQVVfeXFMUHdDampCS00xeXpQczVTMjZmY1JtdlI4Zm42TmxKeWR6TzAtdDhOWnpWRUhKeU9fMzV4ZGZDWUk5QkUway1SdlFxam50WE5lOWlmamtKOWF0VmpXVk9SZkhGSkdWbEhnZHFyQ1BOWU93VjVPc01neFlIOHFkOTJJRjVUeGZqY0QzTGJaWGVnc3NuVnl5ODFxRlgtTEdXWGh0MHlqS052Q3JxSkNZbTFFcFZHdmZkeWRjT0NyTzlLdXltZmU3bDR2RVZhZldoZW5Udkx5anFVSTc3NGg0TGFteTc?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNMEk2MUVJcFJpNDU3cmpNNjlvaVNxd0JlMFZLUHpjcnc2QXlxNlZOYVU4UkZYVUpjX0FZTmVHVkQxc044UE9DRGRRWkQyVzNCck1pbzFEbXZYZHAxVXNuVkl4UnJrTWdEY1lQZTJSWjdHdF9aUVFlUldHcGJtd0dpMXJGOTlxV1J3Qi1IU0Q2VExGT0NNMGdpN3hDVFI4NGswcjZvZE5n?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Doctor behind 30 cancer approvals now steers TuHURA's AML effort", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQVDNGQ2lVejRBRFpDS0luX3NNNHM3M1A0ZmtMaDJuU25tVXY0RGR5b1Bnb24xSndqM3AwRm4yUTVvN1AxaFBTNUZRcVZPNXU4QWRqdC1zdjFxS0R0WEhMdGVMenVLNGh5eGVtalV1cl9Fc1hhNC1aUFR1cW90Zk10cDF4Q2hWYzFkMkRVaFcwc3lFTjNJVjFub0JBMUdnQVpIZTdYaWlmLXhVOHdCd2tpb1hWYUdZbjBVN1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Common Stock (HURA) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1ZTUg4bklEalFpQXpCalMzTGhEeXREcTdHbkpwX2RyaV9Tc0U1ellLdjE1MEJYMHdfM1puRjhjTWRqcXdnX2ZEMEstX2JNUVg2VXhjckY4dw?oc=5", "source_name": "Gotrade", "published_at": "2026-03-18T20:03:30+00:00", "published_display": "18 Mar 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNeWlQVUUtZm5xNHg3UWVRcHlMa2VJTFR3ekw2ZExnNElEQWlDRTBxbjJ5bnVXNGR2NjRHaEVST3lYU0MwRURwWlJsNTdmd0F0cXJRRUMxQVYwQUdoekYxN1pOT3NveXJVWG11eTZpNmcwcmdvZXlSM3dwRk1ERFJRb0xpdWtSU1JWSHJiSjB4SzlVc28xV21sQjJ1ZVlmZFhCdy0wd3BJd2ZaVEZkWmVyQjNQeXIwZ3BINmZzNnpuN20zVy13RURTQ1lpT2FtQ2pZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgJBVV95cUxOUmtEVURrVktoSjFuanlqYl9JR1VRRzRKRm9qOERWRHNzM0lxQ3R1SzhCNjJFNnp6TnVYWmRZc0NEMm1Gc0NFMjVVZVIzNzNZR3h5N1ZRbnpCakpMTVg0N0lONEl0NnJEUEpuXzhlRnJMekl5WGNmM0ZwVTJqMkJia25RQllvNzBpcFR5YjlIN2ZleGh3Z3Jwd24xQWIwZUR6NWl3b05zZnRhRFp4QmR6WEc2TmFobHl5SkN5MlZJWEVaNTl5TlNGVG1nMVdFbVJkLWVBLVdHcUlpSXFGVnJVSFdIbDdiZEVCRm1aTlV2VjJ5MUgwV0pqQ1FhaGlZV0JYbnc4Tmk5dGZXNFh4ZUhXSnpFQmFEQjlIcjgyc3JvbWRZaVZGcFpQQXU1bmlPam9qS1NzU1JNYVBHVWhpZ0E?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxONThocXpBVUgxczRTZnBKRUo4RWkxS0dJdl9tN0lad1V4VkVRNDNqYmRLdzZXU01hd3JSNl9iUWpDWmNRdV9yQkJ1R05PT0hXZnRFVEhzSnVwREF3NUV3eHU4TVYwRlpxbTlWVG1IZUg3aHlrVXpGbUw0Tk9hdklrTVhQSGxCYzFranFOVnYyMmlqWE45MUstcEE1SjFRUnlOUTl2aXdBcE1nQ0VjRi1qcmRWb0tOTTdDaHdLaWttUUl0T0s2SVJB?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences announces $15.6 million registered direct offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQR3VIUklONE5LNEpOZVR0SEJpWjBtWTVRclpfMlc2MXE4b2JpNzMyNS1hSVRuMXJOVlpzTnZBQTg5S0M4SVhURnA0LUdUOUNoenVIMFpYbFlpT293X1U2VTROUEtpbzN4Mjl3bzJMdTh0MkNKNzRjcHlHb1hwbjN1TVN5QjItUUVHSTFaZ2Vfc2JmMU50cGRpa0h3Mi1tNHRHME5tN0Q5Q0h3NTgwMEdOVU90VzdFZWxTNWtJM05rLWV1Zw?oc=5", "source_name": "Investing.com", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The recent pullback must have dismayed TuHURA Biosciences, Inc. (NASDAQ:HURA) insiders who own 43% of the company", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HURA Stock Price and Chart \u2014 NASDAQ:HURA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1sYTNGVE1naVdiNmdYOFNkcnVzOVdVc2NhLXpTczBhLXdEN3pkWDJHM0l0UHMxWGJDMnFMblVKU1BUb0NvaS1OTEp5aXhfNW5ieWg3QlI5QWVJNTFS?oc=5", "source_name": "TradingView", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-03T07:00:00+00:00", "published_display": "03 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOcUJaeWlLNHVmaGlNN2VRYmpZZlRuc3BFekNPYWUxcFFEd1lwd1BJekJkSXg0TkloaEZOR1o2ZjVmUEFETEp4WEtXazhnYThpV0gzOUdoUFI5clhkYU1kV2d5LXNWZDdTNEtKTzFlSDRMTC1LLWM2TTUta2lpZUpuT1NPTF8?oc=5", "source_name": "Market source", "published_at": "2025-04-18T07:00:00+00:00", "published_display": "18 Apr 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TuHURA Biosciences (HURA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9zVkFNbDIwam1oOTVzVHMwdURvc0dxZk0wbUZKMXIxNWdrLTNmN281aHc5a3RJbUlHZXB4Y1Brd25zNnNvZ2tpS1hUcEw5WENWX2tEZThSa2lNZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-11-05T15:13:54+00:00", "published_display": "05 Nov 2024 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxPMkNFOVFBSlNXVmFQRlFCeEhCQnFDSDZBQWI4UHVhTWp4bXJEWXNVcVVDYUtVaDFRd0QyVXpvZTVueF9OQWNsYUYzTGxwVzk4N19FZUtJWTdjZ1AtQ3pHcWJMX1prdmJpTGxnU3I3Z3RNV05VMjRnSnhncDUxc19KS2FKaW9WZUJQZFQ3R3c0NzhRdGRJdGRIaFBneC0wTVZaVkhHRGo0LXhTdlkzMGVJbkRrSW5aQjZGRHlYbVhoQldFVWlrNGo5d3hid2RtTjFGM0hfMDRkZGxCeEJRZ3gxVFNnRGJXdzNjenRhUkNqeDJ2UzQ3N0NTNmFoUjRqbzE4ZmJackpHZXNwZw?oc=5", "source_name": "PR Newswire", "published_at": "2024-10-16T07:00:00+00:00", "published_display": "16 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 59, "sentiment_summary": {"positive": 6, "negative": 11, "neutral": 42, "score": 48, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.21, "count": 19}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 6, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 2.39, "latest_week": "2026-07-10", "one_week_move": -2.0, "four_week_move": 3.0, "twelve_week_move": -18.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.073354, "market_dynamics_buy_signal": false, "relative_strength": 1.868341, "fair_value_gap": -86.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.6172, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.0% over one week, +3.0% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Market source", "count": 9}, {"label": "PR Newswire", "count": 9}, {"label": "www.marketscreener.com", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Investing.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 5}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.0% over one week, +3.0% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form DEF 14A TuHURA Biosciences For: 9 July By Investing.com"}], "updated_at": "2026-07-17T22:37:56.349235+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}